Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:ESTA NASDAQ:LMAT NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$17.03+3.7%$13.14$8.80▼$32.71$732.15M3.04912,751 shs1.06 million shsESTAEstablishment Labs$88.03-0.8%$78.32$33.35▼$92.83$2.61B1.06794,951 shs271,510 shsLMATLeMaitre Vascular$102.74+0.3%$97.90$79.00▼$118.01$2.34B0.52335,398 shs311,458 shsTMDXTransMedics Group$71.23-1.3%$71.52$60.10▼$156.00$2.49B1.89996,398 shs455,584 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+3.65%+1.61%+24.13%+92.21%+28.24%ESTAEstablishment Labs-0.83%-1.37%+10.79%+46.25%+95.36%LMATLeMaitre Vascular+0.33%-0.14%+11.26%-10.36%+21.51%TMDXTransMedics Group-1.33%+3.44%-4.73%-37.52%-43.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$17.03+3.7%$13.14$8.80▼$32.71$732.15M3.04912,751 shs1.06 million shsESTAEstablishment Labs$88.03-0.8%$78.32$33.35▼$92.83$2.61B1.06794,951 shs271,510 shsLMATLeMaitre Vascular$102.74+0.3%$97.90$79.00▼$118.01$2.34B0.52335,398 shs311,458 shsTMDXTransMedics Group$71.23-1.3%$71.52$60.10▼$156.00$2.49B1.89996,398 shs455,584 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+3.65%+1.61%+24.13%+92.21%+28.24%ESTAEstablishment Labs-0.83%-1.37%+10.79%+46.25%+95.36%LMATLeMaitre Vascular+0.33%-0.14%+11.26%-10.36%+21.51%TMDXTransMedics Group-1.33%+3.44%-4.73%-37.52%-43.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.64Moderate Buy$19.7015.68% UpsideESTAEstablishment Labs 2.67Moderate Buy$89.711.91% UpsideLMATLeMaitre Vascular 2.50Moderate Buy$112.609.60% UpsideTMDXTransMedics Group 2.38Hold$134.5088.82% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, ESTA, TMDX, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026ESTAEstablishment Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$76.00 ➝ $92.007/6/2026LMATLeMaitre Vascular Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/6/2026TMDXTransMedics Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/1/2026TMDXTransMedics Group TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$120.006/30/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/30/2026TMDXTransMedics Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$124.006/24/2026ESTAEstablishment Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/18/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$75.00 ➝ $80.006/9/2026TMDXTransMedics Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/8/2026ESTAEstablishment Labs TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$120.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$100.25M7.57N/AN/A$6.53 per share2.61ESTAEstablishment Labs$211.08M12.27N/AN/A$0.81 per share108.68LMATLeMaitre Vascular$249.60M9.41$2.91 per share35.28$17.35 per share5.92TMDXTransMedics Group$605.49M4.07$3.88 per share18.38$13.79 per share5.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/AESTAEstablishment Labs-$51.06M-$1.49N/A628.79N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7137.9131.422.8424.35%15.36%9.78%8/4/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4016.1920.24N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest BBNX, ESTA, TMDX, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ESTAEstablishment Labs-$0.34N/AN/AN/A$65.77 millionN/A8/4/2026Q2 2026LMATLeMaitre Vascular$0.81N/AN/AN/A$71.47 millionN/A7/30/2026Q2 2026TMDXTransMedics Group$0.51N/AN/AN/A$184.57 millionN/A5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million4/21/2026Q1 2026BBNXBeta Bionics-$0.53-$0.49+$0.04-$0.49N/A$27.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.000.97%+16.05%36.90%14 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest BBNX, ESTA, TMDX, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.251%5/21/20265/21/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A10.699.67ESTAEstablishment Labs16.822.961.91LMATLeMaitre Vascular0.4214.3212.20TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AESTAEstablishment Labs72.91%LMATLeMaitre Vascular84.64%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipBBNXBeta Bionics5.30%ESTAEstablishment Labs9.99%LMATLeMaitre Vascular7.40%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29444.56 million42.20 millionN/AESTAEstablishment Labs1,00429.43 million26.49 millionOptionableLMATLeMaitre Vascular49022.85 million21.16 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableBBNX, ESTA, TMDX, and LMAT HeadlinesRecent News About These CompaniesIs TransMedics Group, Inc. (TMDX) Stock Still a MedTech Growth Opportunity After Analyst Target Cut?July 8 at 1:46 PM | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Daiichi Sankyo Company (OtherDSKYF), Vertex Pharmaceuticals (VRTX) and TransMedics Group (TMDX)July 8 at 8:45 AM | theglobeandmail.comTransMedics Completes PAD Aviation Investment to Expand in EuropeJuly 7, 2026 | zacks.comTransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbHJuly 6, 2026 | prnewswire.comWhere Will TransMedics Group Stock Be in 10 Years?July 3, 2026 | fool.comTMDX stock rallies as analyst sees 77% upside — here’s whyJuly 1, 2026 | msn.comTransMedics: The Margins Must RecoverJuly 1, 2026 | seekingalpha.comReasons to Retain TransMedics Stock in Your Portfolio for NowJune 30, 2026 | zacks.comTransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Canaccord Genuity GroupJune 30, 2026 | marketbeat.comWhat a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock DropJune 25, 2026 | theglobeandmail.comVirtu Financial LLC Buys 22,202 Shares of TransMedics Group, Inc. $TMDXJune 19, 2026 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $80.00June 18, 2026 | marketbeat.comInsider Selling: TransMedics Group (NASDAQ:TMDX) Director Sells 9,624 Shares of StockJune 18, 2026 | insidertrades.comJohnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP InvestmentsJune 12, 2026 | globenewswire.comTransMedics Group Inc.June 11, 2026 | barrons.comTransMedics: Why I'm Still Bullish After The CollapseJune 9, 2026 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)June 6, 2026 | theglobeandmail.comWill Analyst Focus on TransMedics’ OCS Platform and Financial Metrics Change TransMedics Group’s (TMDX) Narrative?June 6, 2026 | uk.finance.yahoo.comTransMedics Group, Inc. (TMDX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4, 2026 | seekingalpha.comTransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?June 4, 2026 | zacks.comReasons to Retain TransMedics Stock in Your Portfolio for NowMay 28, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Qualcomm Goes All-In: The $10B Bet to Crush NVIDIABy Jeffrey Neal Johnson | June 18, 2026Investors Are Buying Into Sweetgreen Again—Should They?By Jennifer Ryan Woods | June 22, 2026Energy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 2026Domino's Stock Slides to 52-Week Low as Investors Digest CEO ChangeBy Jennifer Ryan Woods | June 25, 2026BBNX, ESTA, TMDX, and LMAT Company DescriptionsBeta Bionics NASDAQ:BBNX$17.03 +0.60 (+3.65%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$17.31 +0.28 (+1.63%) As of 07/10/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Establishment Labs NASDAQ:ESTA$88.03 -0.74 (-0.83%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$88.00 -0.03 (-0.03%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.LeMaitre Vascular NASDAQ:LMAT$102.74 +0.34 (+0.33%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$102.88 +0.14 (+0.13%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.TransMedics Group NASDAQ:TMDX$71.23 -0.96 (-1.33%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$71.05 -0.18 (-0.25%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
